nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—SLC6A4—chronic obstructive pulmonary disease	0.154	0.312	CbGaD
Fluoxetine—CYP1A2—chronic obstructive pulmonary disease	0.14	0.284	CbGaD
Fluoxetine—HTR2A—chronic obstructive pulmonary disease	0.118	0.24	CbGaD
Fluoxetine—ALB—chronic obstructive pulmonary disease	0.0809	0.164	CbGaD
Fluoxetine—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0274	0.0885	CbGbCtD
Fluoxetine—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0274	0.0885	CbGbCtD
Fluoxetine—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0227	0.0735	CbGbCtD
Fluoxetine—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0227	0.0735	CbGbCtD
Fluoxetine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0215	0.0694	CbGbCtD
Fluoxetine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0208	0.0672	CbGbCtD
Fluoxetine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0208	0.0672	CbGbCtD
Fluoxetine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0185	0.0599	CbGbCtD
Fluoxetine—ALB—Prednisone—chronic obstructive pulmonary disease	0.0177	0.0573	CbGbCtD
Fluoxetine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0175	0.0564	CbGbCtD
Fluoxetine—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0172	0.0557	CbGbCtD
Fluoxetine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0118	0.0381	CbGbCtD
Fluoxetine—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0115	0.0371	CbGbCtD
Fluoxetine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0112	0.0364	CbGbCtD
Fluoxetine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.01	0.0324	CbGbCtD
Fluoxetine—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00982	0.0317	CbGbCtD
Fluoxetine—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00927	0.03	CbGbCtD
Fluoxetine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00588	0.019	CbGbCtD
Fluoxetine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00555	0.018	CbGbCtD
Fluoxetine—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.0052	0.352	CbGeAlD
Fluoxetine—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00189	0.128	CbGeAlD
Fluoxetine—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.0006	0.0406	CbGeAlD
Fluoxetine—Cinacalcet—CYP1A2—chronic obstructive pulmonary disease	0.000562	0.244	CrCbGaD
Fluoxetine—SLC6A2—respiratory system—chronic obstructive pulmonary disease	0.000528	0.0357	CbGeAlD
Fluoxetine—SIGMAR1—bronchus—chronic obstructive pulmonary disease	0.00049	0.0332	CbGeAlD
Fluoxetine—Duloxetine—SLC6A4—chronic obstructive pulmonary disease	0.000484	0.21	CrCbGaD
Fluoxetine—SIGMAR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00048	0.0325	CbGeAlD
Fluoxetine—Duloxetine—CYP1A2—chronic obstructive pulmonary disease	0.00044	0.191	CrCbGaD
Fluoxetine—SIGMAR1—trachea—chronic obstructive pulmonary disease	0.00044	0.0298	CbGeAlD
Fluoxetine—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000406	0.0275	CbGeAlD
Fluoxetine—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000391	0.0265	CbGeAlD
Fluoxetine—CYP2B6—respiratory system—chronic obstructive pulmonary disease	0.000389	0.0263	CbGeAlD
Fluoxetine—ORM1—lung—chronic obstructive pulmonary disease	0.000374	0.0253	CbGeAlD
Fluoxetine—Duloxetine—HTR2A—chronic obstructive pulmonary disease	0.000372	0.161	CrCbGaD
Fluoxetine—CYP2B6—bronchus—chronic obstructive pulmonary disease	0.00032	0.0217	CbGeAlD
Fluoxetine—SLC6A4—lung—chronic obstructive pulmonary disease	0.000318	0.0216	CbGeAlD
Fluoxetine—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.000317	0.0215	CbGeAlD
Fluoxetine—SIGMAR1—lung—chronic obstructive pulmonary disease	0.000316	0.0214	CbGeAlD
Fluoxetine—SLC6A2—lung—chronic obstructive pulmonary disease	0.00028	0.019	CbGeAlD
Fluoxetine—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000279	0.0189	CbGeAlD
Fluoxetine—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000256	0.0173	CbGeAlD
Fluoxetine—Atomoxetine—SLC6A4—chronic obstructive pulmonary disease	0.000253	0.11	CrCbGaD
Fluoxetine—HTR2A—trachea—chronic obstructive pulmonary disease	0.000234	0.0159	CbGeAlD
Fluoxetine—CYP1A2—lung—chronic obstructive pulmonary disease	0.000215	0.0146	CbGeAlD
Fluoxetine—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000208	0.0141	CbGeAlD
Fluoxetine—CYP3A5—lung—chronic obstructive pulmonary disease	0.000208	0.0141	CbGeAlD
Fluoxetine—CYP2B6—lung—chronic obstructive pulmonary disease	0.000207	0.014	CbGeAlD
Fluoxetine—Atomoxetine—HTR2A—chronic obstructive pulmonary disease	0.000195	0.0844	CrCbGaD
Fluoxetine—HTR2A—lung—chronic obstructive pulmonary disease	0.000168	0.0114	CbGeAlD
Fluoxetine—ABCB1—trachea—chronic obstructive pulmonary disease	0.000154	0.0104	CbGeAlD
Fluoxetine—ABCB1—lung—chronic obstructive pulmonary disease	0.00011	0.00748	CbGeAlD
Fluoxetine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	9.46e-05	0.000655	CcSEcCtD
Fluoxetine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	9.43e-05	0.000652	CcSEcCtD
Fluoxetine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	9.39e-05	0.000649	CcSEcCtD
Fluoxetine—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	9.37e-05	0.000648	CcSEcCtD
Fluoxetine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	9.34e-05	0.000646	CcSEcCtD
Fluoxetine—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	9.34e-05	0.000646	CcSEcCtD
Fluoxetine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	9.27e-05	0.000641	CcSEcCtD
Fluoxetine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	9.23e-05	0.000639	CcSEcCtD
Fluoxetine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	9.2e-05	0.000636	CcSEcCtD
Fluoxetine—Infection—Salbutamol—chronic obstructive pulmonary disease	9.14e-05	0.000632	CcSEcCtD
Fluoxetine—Hypotension—Formoterol—chronic obstructive pulmonary disease	9.11e-05	0.00063	CcSEcCtD
Fluoxetine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	9.11e-05	0.00063	CcSEcCtD
Fluoxetine—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	9.1e-05	0.000629	CcSEcCtD
Fluoxetine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	9.06e-05	0.000627	CcSEcCtD
Fluoxetine—Shock—Salbutamol—chronic obstructive pulmonary disease	9.05e-05	0.000626	CcSEcCtD
Fluoxetine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	9.04e-05	0.000625	CcSEcCtD
Fluoxetine—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	9.01e-05	0.000623	CcSEcCtD
Fluoxetine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	8.98e-05	0.000621	CcSEcCtD
Fluoxetine—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	8.97e-05	0.00062	CcSEcCtD
Fluoxetine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	8.94e-05	0.000618	CcSEcCtD
Fluoxetine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	8.9e-05	0.000615	CcSEcCtD
Fluoxetine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	8.89e-05	0.000615	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	8.88e-05	0.000614	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	8.88e-05	0.000614	CcSEcCtD
Fluoxetine—Insomnia—Formoterol—chronic obstructive pulmonary disease	8.81e-05	0.00061	CcSEcCtD
Fluoxetine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	8.81e-05	0.00061	CcSEcCtD
Fluoxetine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	8.77e-05	0.000607	CcSEcCtD
Fluoxetine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	8.76e-05	0.000606	CcSEcCtD
Fluoxetine—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	8.72e-05	0.000603	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	8.7e-05	0.000601	CcSEcCtD
Fluoxetine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	8.69e-05	0.000601	CcSEcCtD
Fluoxetine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	8.69e-05	0.000601	CcSEcCtD
Fluoxetine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	8.66e-05	0.000599	CcSEcCtD
Fluoxetine—Somnolence—Formoterol—chronic obstructive pulmonary disease	8.66e-05	0.000599	CcSEcCtD
Fluoxetine—Insomnia—Montelukast—chronic obstructive pulmonary disease	8.63e-05	0.000597	CcSEcCtD
Fluoxetine—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	8.6e-05	0.000595	CcSEcCtD
Fluoxetine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	8.6e-05	0.000595	CcSEcCtD
Fluoxetine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	8.58e-05	0.000593	CcSEcCtD
Fluoxetine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	8.58e-05	0.000593	CcSEcCtD
Fluoxetine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	8.57e-05	0.000593	CcSEcCtD
Fluoxetine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	8.54e-05	0.000591	CcSEcCtD
Fluoxetine—Injury—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000587	CcSEcCtD
Fluoxetine—Somnolence—Montelukast—chronic obstructive pulmonary disease	8.48e-05	0.000587	CcSEcCtD
Fluoxetine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	8.47e-05	0.000586	CcSEcCtD
Fluoxetine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	8.45e-05	0.000584	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	8.41e-05	0.000582	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	8.41e-05	0.000582	CcSEcCtD
Fluoxetine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	8.4e-05	0.000581	CcSEcCtD
Fluoxetine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	8.4e-05	0.000581	CcSEcCtD
Fluoxetine—Fatigue—Formoterol—chronic obstructive pulmonary disease	8.4e-05	0.000581	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	8.38e-05	0.00058	CcSEcCtD
Fluoxetine—Pain—Arformoterol—chronic obstructive pulmonary disease	8.33e-05	0.000576	CcSEcCtD
Fluoxetine—Constipation—Arformoterol—chronic obstructive pulmonary disease	8.33e-05	0.000576	CcSEcCtD
Fluoxetine—Pain—Formoterol—chronic obstructive pulmonary disease	8.33e-05	0.000576	CcSEcCtD
Fluoxetine—Constipation—Formoterol—chronic obstructive pulmonary disease	8.33e-05	0.000576	CcSEcCtD
Fluoxetine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	8.32e-05	0.000576	CcSEcCtD
Fluoxetine—Amnesia—Prednisone—chronic obstructive pulmonary disease	8.3e-05	0.000574	CcSEcCtD
Fluoxetine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	8.3e-05	0.000574	CcSEcCtD
Fluoxetine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	8.26e-05	0.000571	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	8.24e-05	0.00057	CcSEcCtD
Fluoxetine—Fatigue—Montelukast—chronic obstructive pulmonary disease	8.23e-05	0.000569	CcSEcCtD
Fluoxetine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	8.2e-05	0.000567	CcSEcCtD
Fluoxetine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	8.18e-05	0.000566	CcSEcCtD
Fluoxetine—Pain—Montelukast—chronic obstructive pulmonary disease	8.16e-05	0.000565	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	8.16e-05	0.000564	CcSEcCtD
Fluoxetine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	8.14e-05	0.000563	CcSEcCtD
Fluoxetine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	8.11e-05	0.000561	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	8.11e-05	0.000561	CcSEcCtD
Fluoxetine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	8.1e-05	0.00056	CcSEcCtD
Fluoxetine—Purpura—Prednisone—chronic obstructive pulmonary disease	8.09e-05	0.00056	CcSEcCtD
Fluoxetine—Rash—Aminophylline—chronic obstructive pulmonary disease	8.07e-05	0.000558	CcSEcCtD
Fluoxetine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	8.07e-05	0.000558	CcSEcCtD
Fluoxetine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	8.04e-05	0.000556	CcSEcCtD
Fluoxetine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	8.03e-05	0.000555	CcSEcCtD
Fluoxetine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	8.03e-05	0.000555	CcSEcCtD
Fluoxetine—Headache—Aminophylline—chronic obstructive pulmonary disease	8.02e-05	0.000555	CcSEcCtD
Fluoxetine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	8e-05	0.000553	CcSEcCtD
Fluoxetine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	7.98e-05	0.000552	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	7.97e-05	0.000551	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	7.97e-05	0.000551	CcSEcCtD
Fluoxetine—Lethargy—Prednisone—chronic obstructive pulmonary disease	7.96e-05	0.000551	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	7.94e-05	0.000549	CcSEcCtD
Fluoxetine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	7.93e-05	0.000549	CcSEcCtD
Fluoxetine—Pain—Salbutamol—chronic obstructive pulmonary disease	7.87e-05	0.000544	CcSEcCtD
Fluoxetine—Constipation—Salbutamol—chronic obstructive pulmonary disease	7.87e-05	0.000544	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	7.8e-05	0.00054	CcSEcCtD
Fluoxetine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	7.8e-05	0.00054	CcSEcCtD
Fluoxetine—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	7.8e-05	0.00054	CcSEcCtD
Fluoxetine—Urticaria—Formoterol—chronic obstructive pulmonary disease	7.74e-05	0.000535	CcSEcCtD
Fluoxetine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	7.74e-05	0.000535	CcSEcCtD
Fluoxetine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	7.7e-05	0.000533	CcSEcCtD
Fluoxetine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	7.7e-05	0.000533	CcSEcCtD
Fluoxetine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	7.7e-05	0.000533	CcSEcCtD
Fluoxetine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	7.7e-05	0.000533	CcSEcCtD
Fluoxetine—Affect lability—Prednisone—chronic obstructive pulmonary disease	7.68e-05	0.000531	CcSEcCtD
Fluoxetine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	7.68e-05	0.000531	CcSEcCtD
Fluoxetine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	7.62e-05	0.000527	CcSEcCtD
Fluoxetine—Rash—Tiotropium—chronic obstructive pulmonary disease	7.61e-05	0.000527	CcSEcCtD
Fluoxetine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	7.61e-05	0.000526	CcSEcCtD
Fluoxetine—Nausea—Aminophylline—chronic obstructive pulmonary disease	7.6e-05	0.000526	CcSEcCtD
Fluoxetine—Urticaria—Montelukast—chronic obstructive pulmonary disease	7.58e-05	0.000524	CcSEcCtD
Fluoxetine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	7.58e-05	0.000524	CcSEcCtD
Fluoxetine—Headache—Tiotropium—chronic obstructive pulmonary disease	7.56e-05	0.000523	CcSEcCtD
Fluoxetine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	7.56e-05	0.000523	CcSEcCtD
Fluoxetine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	7.54e-05	0.000522	CcSEcCtD
Fluoxetine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	7.54e-05	0.000522	CcSEcCtD
Fluoxetine—Face oedema—Prednisone—chronic obstructive pulmonary disease	7.53e-05	0.000521	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	7.52e-05	0.00052	CcSEcCtD
Fluoxetine—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	7.47e-05	0.000516	CcSEcCtD
Fluoxetine—Irritability—Prednisone—chronic obstructive pulmonary disease	7.45e-05	0.000515	CcSEcCtD
Fluoxetine—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	7.43e-05	0.000514	CcSEcCtD
Fluoxetine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	7.42e-05	0.000513	CcSEcCtD
Fluoxetine—Mood swings—Prednisone—chronic obstructive pulmonary disease	7.39e-05	0.000511	CcSEcCtD
Fluoxetine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	7.31e-05	0.000506	CcSEcCtD
Fluoxetine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	7.27e-05	0.000503	CcSEcCtD
Fluoxetine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	7.27e-05	0.000503	CcSEcCtD
Fluoxetine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	7.18e-05	0.000497	CcSEcCtD
Fluoxetine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	7.18e-05	0.000497	CcSEcCtD
Fluoxetine—Nausea—Tiotropium—chronic obstructive pulmonary disease	7.17e-05	0.000496	CcSEcCtD
Fluoxetine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	7.16e-05	0.000495	CcSEcCtD
Fluoxetine—Dry skin—Prednisone—chronic obstructive pulmonary disease	7.15e-05	0.000495	CcSEcCtD
Fluoxetine—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	7.1e-05	0.000491	CcSEcCtD
Fluoxetine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	7.03e-05	0.000486	CcSEcCtD
Fluoxetine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	6.99e-05	0.000484	CcSEcCtD
Fluoxetine—Asthenia—Formoterol—chronic obstructive pulmonary disease	6.99e-05	0.000484	CcSEcCtD
Fluoxetine—Pruritus—Formoterol—chronic obstructive pulmonary disease	6.89e-05	0.000477	CcSEcCtD
Fluoxetine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	6.89e-05	0.000477	CcSEcCtD
Fluoxetine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	6.88e-05	0.000476	CcSEcCtD
Fluoxetine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	6.88e-05	0.000476	CcSEcCtD
Fluoxetine—Asthenia—Montelukast—chronic obstructive pulmonary disease	6.85e-05	0.000474	CcSEcCtD
Fluoxetine—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	6.79e-05	0.00047	CcSEcCtD
Fluoxetine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	6.78e-05	0.000469	CcSEcCtD
Fluoxetine—Pruritus—Montelukast—chronic obstructive pulmonary disease	6.75e-05	0.000467	CcSEcCtD
Fluoxetine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	6.67e-05	0.000461	CcSEcCtD
Fluoxetine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	6.67e-05	0.000461	CcSEcCtD
Fluoxetine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	6.64e-05	0.000459	CcSEcCtD
Fluoxetine—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	6.61e-05	0.000457	CcSEcCtD
Fluoxetine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	6.6e-05	0.000457	CcSEcCtD
Fluoxetine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	6.57e-05	0.000454	CcSEcCtD
Fluoxetine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	6.53e-05	0.000452	CcSEcCtD
Fluoxetine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	6.51e-05	0.00045	CcSEcCtD
Fluoxetine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	6.44e-05	0.000446	CcSEcCtD
Fluoxetine—Dizziness—Formoterol—chronic obstructive pulmonary disease	6.44e-05	0.000446	CcSEcCtD
Fluoxetine—Dizziness—Montelukast—chronic obstructive pulmonary disease	6.31e-05	0.000437	CcSEcCtD
Fluoxetine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	6.3e-05	0.000435	CcSEcCtD
Fluoxetine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	6.21e-05	0.00043	CcSEcCtD
Fluoxetine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	6.2e-05	0.000429	CcSEcCtD
Fluoxetine—Vomiting—Formoterol—chronic obstructive pulmonary disease	6.2e-05	0.000429	CcSEcCtD
Fluoxetine—Rash—Arformoterol—chronic obstructive pulmonary disease	6.14e-05	0.000425	CcSEcCtD
Fluoxetine—Rash—Formoterol—chronic obstructive pulmonary disease	6.14e-05	0.000425	CcSEcCtD
Fluoxetine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	6.14e-05	0.000425	CcSEcCtD
Fluoxetine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	6.14e-05	0.000425	CcSEcCtD
Fluoxetine—Weight increased—Prednisone—chronic obstructive pulmonary disease	6.14e-05	0.000425	CcSEcCtD
Fluoxetine—Headache—Formoterol—chronic obstructive pulmonary disease	6.1e-05	0.000422	CcSEcCtD
Fluoxetine—Headache—Arformoterol—chronic obstructive pulmonary disease	6.1e-05	0.000422	CcSEcCtD
Fluoxetine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	6.1e-05	0.000422	CcSEcCtD
Fluoxetine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	6.08e-05	0.000421	CcSEcCtD
Fluoxetine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	6.08e-05	0.000421	CcSEcCtD
Fluoxetine—Vomiting—Montelukast—chronic obstructive pulmonary disease	6.07e-05	0.00042	CcSEcCtD
Fluoxetine—Rash—Montelukast—chronic obstructive pulmonary disease	6.02e-05	0.000416	CcSEcCtD
Fluoxetine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	6.01e-05	0.000416	CcSEcCtD
Fluoxetine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	6e-05	0.000415	CcSEcCtD
Fluoxetine—Depression—Prednisone—chronic obstructive pulmonary disease	6e-05	0.000415	CcSEcCtD
Fluoxetine—Headache—Montelukast—chronic obstructive pulmonary disease	5.98e-05	0.000414	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	5.93e-05	0.00041	CcSEcCtD
Fluoxetine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	5.91e-05	0.000409	CcSEcCtD
Fluoxetine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	5.89e-05	0.000408	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	5.89e-05	0.000408	CcSEcCtD
Fluoxetine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	5.85e-05	0.000405	CcSEcCtD
Fluoxetine—Malaise—Prednisolone—chronic obstructive pulmonary disease	5.83e-05	0.000403	CcSEcCtD
Fluoxetine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	5.81e-05	0.000402	CcSEcCtD
Fluoxetine—Rash—Salbutamol—chronic obstructive pulmonary disease	5.8e-05	0.000401	CcSEcCtD
Fluoxetine—Syncope—Prednisolone—chronic obstructive pulmonary disease	5.8e-05	0.000401	CcSEcCtD
Fluoxetine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	5.8e-05	0.000401	CcSEcCtD
Fluoxetine—Nausea—Arformoterol—chronic obstructive pulmonary disease	5.79e-05	0.0004	CcSEcCtD
Fluoxetine—Nausea—Formoterol—chronic obstructive pulmonary disease	5.79e-05	0.0004	CcSEcCtD
Fluoxetine—Headache—Salbutamol—chronic obstructive pulmonary disease	5.76e-05	0.000399	CcSEcCtD
Fluoxetine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	5.68e-05	0.000393	CcSEcCtD
Fluoxetine—Nausea—Montelukast—chronic obstructive pulmonary disease	5.67e-05	0.000392	CcSEcCtD
Fluoxetine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	5.6e-05	0.000388	CcSEcCtD
Fluoxetine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	5.58e-05	0.000386	CcSEcCtD
Fluoxetine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	5.49e-05	0.00038	CcSEcCtD
Fluoxetine—Nausea—Salbutamol—chronic obstructive pulmonary disease	5.47e-05	0.000378	CcSEcCtD
Fluoxetine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	5.44e-05	0.000376	CcSEcCtD
Fluoxetine—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	5.42e-05	0.000375	CcSEcCtD
Fluoxetine—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	5.4e-05	0.000373	CcSEcCtD
Fluoxetine—Hallucination—Prednisone—chronic obstructive pulmonary disease	5.37e-05	0.000371	CcSEcCtD
Fluoxetine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	5.28e-05	0.000365	CcSEcCtD
Fluoxetine—Shock—Prednisolone—chronic obstructive pulmonary disease	5.19e-05	0.000359	CcSEcCtD
Fluoxetine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	5.15e-05	0.000356	CcSEcCtD
Fluoxetine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	5.1e-05	0.000353	CcSEcCtD
Fluoxetine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	4.82e-05	0.000334	CcSEcCtD
Fluoxetine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	4.77e-05	0.00033	CcSEcCtD
Fluoxetine—Alopecia—Prednisone—chronic obstructive pulmonary disease	4.77e-05	0.00033	CcSEcCtD
Fluoxetine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	4.74e-05	0.000328	CcSEcCtD
Fluoxetine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	4.73e-05	0.000327	CcSEcCtD
Fluoxetine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	4.7e-05	0.000325	CcSEcCtD
Fluoxetine—Pain—Prednisolone—chronic obstructive pulmonary disease	4.51e-05	0.000312	CcSEcCtD
Fluoxetine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	4.36e-05	0.000302	CcSEcCtD
Fluoxetine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	4.35e-05	0.000301	CcSEcCtD
Fluoxetine—Anaemia—Prednisone—chronic obstructive pulmonary disease	4.34e-05	0.0003	CcSEcCtD
Fluoxetine—Agitation—Prednisone—chronic obstructive pulmonary disease	4.32e-05	0.000299	CcSEcCtD
Fluoxetine—Angioedema—Prednisone—chronic obstructive pulmonary disease	4.29e-05	0.000297	CcSEcCtD
Fluoxetine—Malaise—Prednisone—chronic obstructive pulmonary disease	4.24e-05	0.000293	CcSEcCtD
Fluoxetine—Vertigo—Prednisone—chronic obstructive pulmonary disease	4.22e-05	0.000292	CcSEcCtD
Fluoxetine—Syncope—Prednisone—chronic obstructive pulmonary disease	4.21e-05	0.000291	CcSEcCtD
Fluoxetine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	4.19e-05	0.00029	CcSEcCtD
Fluoxetine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	4.13e-05	0.000286	CcSEcCtD
Fluoxetine—Convulsion—Prednisone—chronic obstructive pulmonary disease	4.07e-05	0.000282	CcSEcCtD
Fluoxetine—Hypertension—Prednisone—chronic obstructive pulmonary disease	4.06e-05	0.000281	CcSEcCtD
Fluoxetine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	4e-05	0.000277	CcSEcCtD
Fluoxetine—Myalgia—Prednisone—chronic obstructive pulmonary disease	4e-05	0.000277	CcSEcCtD
Fluoxetine—Anxiety—Prednisone—chronic obstructive pulmonary disease	3.99e-05	0.000276	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	3.97e-05	0.000275	CcSEcCtD
Fluoxetine—Discomfort—Prednisone—chronic obstructive pulmonary disease	3.95e-05	0.000273	CcSEcCtD
Fluoxetine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	3.89e-05	0.000269	CcSEcCtD
Fluoxetine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	3.83e-05	0.000265	CcSEcCtD
Fluoxetine—Infection—Prednisone—chronic obstructive pulmonary disease	3.81e-05	0.000264	CcSEcCtD
Fluoxetine—Shock—Prednisone—chronic obstructive pulmonary disease	3.77e-05	0.000261	CcSEcCtD
Fluoxetine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	3.74e-05	0.000259	CcSEcCtD
Fluoxetine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	3.72e-05	0.000258	CcSEcCtD
Fluoxetine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	3.71e-05	0.000256	CcSEcCtD
Fluoxetine—Anorexia—Prednisone—chronic obstructive pulmonary disease	3.66e-05	0.000253	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	3.49e-05	0.000242	CcSEcCtD
Fluoxetine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3.49e-05	0.000241	CcSEcCtD
Fluoxetine—Insomnia—Prednisone—chronic obstructive pulmonary disease	3.47e-05	0.00024	CcSEcCtD
Fluoxetine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	3.44e-05	0.000238	CcSEcCtD
Fluoxetine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	3.38e-05	0.000233	CcSEcCtD
Fluoxetine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	3.33e-05	0.000231	CcSEcCtD
Fluoxetine—Rash—Prednisolone—chronic obstructive pulmonary disease	3.33e-05	0.00023	CcSEcCtD
Fluoxetine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	3.32e-05	0.00023	CcSEcCtD
Fluoxetine—Fatigue—Prednisone—chronic obstructive pulmonary disease	3.31e-05	0.000229	CcSEcCtD
Fluoxetine—Headache—Prednisolone—chronic obstructive pulmonary disease	3.31e-05	0.000229	CcSEcCtD
Fluoxetine—Constipation—Prednisone—chronic obstructive pulmonary disease	3.28e-05	0.000227	CcSEcCtD
Fluoxetine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	3.16e-05	0.000219	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	3.14e-05	0.000217	CcSEcCtD
Fluoxetine—Nausea—Prednisolone—chronic obstructive pulmonary disease	3.13e-05	0.000217	CcSEcCtD
Fluoxetine—Urticaria—Prednisone—chronic obstructive pulmonary disease	3.05e-05	0.000211	CcSEcCtD
Fluoxetine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	3.03e-05	0.00021	CcSEcCtD
Fluoxetine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	3.03e-05	0.00021	CcSEcCtD
Fluoxetine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	2.83e-05	0.000195	CcSEcCtD
Fluoxetine—Asthenia—Prednisone—chronic obstructive pulmonary disease	2.75e-05	0.00019	CcSEcCtD
Fluoxetine—Pruritus—Prednisone—chronic obstructive pulmonary disease	2.71e-05	0.000188	CcSEcCtD
Fluoxetine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.62e-05	0.000181	CcSEcCtD
Fluoxetine—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.54e-05	0.000175	CcSEcCtD
Fluoxetine—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.44e-05	0.000169	CcSEcCtD
Fluoxetine—Rash—Prednisone—chronic obstructive pulmonary disease	2.42e-05	0.000167	CcSEcCtD
Fluoxetine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.42e-05	0.000167	CcSEcCtD
Fluoxetine—Headache—Prednisone—chronic obstructive pulmonary disease	2.4e-05	0.000166	CcSEcCtD
Fluoxetine—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	2.39e-05	0.000664	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	2.39e-05	0.000663	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.35e-05	0.000653	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.34e-05	0.000649	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.34e-05	0.000648	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.32e-05	0.000644	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.3e-05	0.000639	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.29e-05	0.000635	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	2.29e-05	0.000634	CbGpPWpGaD
Fluoxetine—Nausea—Prednisone—chronic obstructive pulmonary disease	2.28e-05	0.000158	CcSEcCtD
Fluoxetine—HTR2C—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.26e-05	0.000628	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	2.24e-05	0.000621	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.24e-05	0.00062	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	2.23e-05	0.00062	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	2.23e-05	0.000619	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	2.22e-05	0.000617	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	2.22e-05	0.000616	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.21e-05	0.000614	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—IL6—chronic obstructive pulmonary disease	2.21e-05	0.000612	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.18e-05	0.000606	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	2.17e-05	0.000603	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.1e-05	0.000583	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.09e-05	0.000581	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	2.08e-05	0.000578	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	2.07e-05	0.000576	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TGFB2—chronic obstructive pulmonary disease	2.07e-05	0.000575	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.03e-05	0.000564	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2e-05	0.000556	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.96e-05	0.000545	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.96e-05	0.000544	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.96e-05	0.000543	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GC—chronic obstructive pulmonary disease	1.95e-05	0.000541	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.93e-05	0.000537	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	1.91e-05	0.000531	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	1.91e-05	0.000529	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	1.86e-05	0.000516	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.82e-05	0.000504	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.81e-05	0.000503	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.81e-05	0.000503	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.8e-05	0.0005	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	1.79e-05	0.000497	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	1.78e-05	0.000494	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.78e-05	0.000493	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.77e-05	0.000491	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	1.76e-05	0.000489	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	1.75e-05	0.000486	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.71e-05	0.000476	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.71e-05	0.000474	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.69e-05	0.000468	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.69e-05	0.000468	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	1.68e-05	0.000465	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.67e-05	0.000464	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GC—chronic obstructive pulmonary disease	1.64e-05	0.000455	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.63e-05	0.000452	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.62e-05	0.000448	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.58e-05	0.000437	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.56e-05	0.000434	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	1.55e-05	0.000431	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	1.54e-05	0.000428	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.53e-05	0.000423	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.51e-05	0.00042	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.5e-05	0.000417	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.49e-05	0.000413	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.49e-05	0.000412	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.48e-05	0.00041	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	1.47e-05	0.000409	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.47e-05	0.000407	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.44e-05	0.000401	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.44e-05	0.000399	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.4e-05	0.000389	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.39e-05	0.000386	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.38e-05	0.000383	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.38e-05	0.000383	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.38e-05	0.000383	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.38e-05	0.000382	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.37e-05	0.000381	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.37e-05	0.00038	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.37e-05	0.00038	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.35e-05	0.000376	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.34e-05	0.000373	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.34e-05	0.000371	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.31e-05	0.000364	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.31e-05	0.000363	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.27e-05	0.000354	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.27e-05	0.000352	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.26e-05	0.000351	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.26e-05	0.000349	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.25e-05	0.000348	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.25e-05	0.000346	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.22e-05	0.000337	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	1.21e-05	0.000337	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.2e-05	0.000333	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.2e-05	0.000333	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	1.2e-05	0.000332	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.19e-05	0.000332	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.19e-05	0.000331	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.18e-05	0.000327	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	1.18e-05	0.000326	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.15e-05	0.000318	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.15e-05	0.000318	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.15e-05	0.000318	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.14e-05	0.000316	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	1.11e-05	0.000309	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.1e-05	0.000304	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.09e-05	0.000303	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	1.08e-05	0.0003	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.08e-05	0.000298	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.07e-05	0.000296	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.06e-05	0.000295	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.05e-05	0.000292	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.04e-05	0.000289	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.03e-05	0.000285	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.02e-05	0.000284	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.01e-05	0.00028	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.95e-06	0.000276	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CTGF—chronic obstructive pulmonary disease	9.61e-06	0.000267	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.39e-06	0.000261	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	9.39e-06	0.000261	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.11e-06	0.000253	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	9.09e-06	0.000252	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.03e-06	0.00025	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.96e-06	0.000249	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	8.86e-06	0.000246	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	8.86e-06	0.000246	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.85e-06	0.000246	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.77e-06	0.000243	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	8.68e-06	0.000241	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.67e-06	0.000241	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.65e-06	0.00024	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	8.5e-06	0.000236	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.24e-06	0.000228	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.16e-06	0.000226	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	8.09e-06	0.000224	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.05e-06	0.000223	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	7.96e-06	0.000221	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.85e-06	0.000218	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.81e-06	0.000217	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	7.76e-06	0.000215	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.75e-06	0.000215	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.53e-06	0.000209	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.45e-06	0.000207	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.42e-06	0.000206	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.4e-06	0.000205	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.38e-06	0.000205	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.34e-06	0.000204	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	7.32e-06	0.000203	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.28e-06	0.000202	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	7.26e-06	0.000201	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	7.25e-06	0.000201	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.22e-06	0.0002	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.12e-06	0.000197	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.09e-06	0.000197	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.09e-06	0.000197	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.04e-06	0.000195	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6.88e-06	0.000191	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.78e-06	0.000188	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.78e-06	0.000188	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.78e-06	0.000188	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.76e-06	0.000188	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.73e-06	0.000187	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.69e-06	0.000186	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	6.68e-06	0.000185	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.63e-06	0.000184	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	6.62e-06	0.000184	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.53e-06	0.000181	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.43e-06	0.000178	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.3e-06	0.000175	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.29e-06	0.000174	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.27e-06	0.000174	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	6.25e-06	0.000174	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.21e-06	0.000172	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	6.2e-06	0.000172	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.16e-06	0.000171	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.15e-06	0.000171	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.13e-06	0.00017	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.12e-06	0.00017	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.1e-06	0.000169	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.78e-06	0.00016	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	5.74e-06	0.000159	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.71e-06	0.000158	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	5.66e-06	0.000157	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.58e-06	0.000155	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.5e-06	0.000153	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.47e-06	0.000152	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.44e-06	0.000151	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.41e-06	0.00015	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.37e-06	0.000149	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.18e-06	0.000144	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.13e-06	0.000142	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.13e-06	0.000142	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.09e-06	0.000141	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.06e-06	0.00014	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.02e-06	0.000139	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5e-06	0.000139	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.94e-06	0.000137	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.86e-06	0.000135	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.84e-06	0.000134	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	4.78e-06	0.000133	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.74e-06	0.000132	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	4.73e-06	0.000131	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.72e-06	0.000131	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.71e-06	0.000131	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.67e-06	0.00013	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.5e-06	0.000125	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.47e-06	0.000124	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.43e-06	0.000123	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—chronic obstructive pulmonary disease	4.37e-06	0.000121	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.37e-06	0.000121	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.35e-06	0.000121	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.29e-06	0.000119	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.29e-06	0.000119	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	4.27e-06	0.000119	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.19e-06	0.000116	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.18e-06	0.000116	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.1e-06	0.000114	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	4.09e-06	0.000113	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.02e-06	0.000112	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.99e-06	0.000111	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.98e-06	0.00011	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.79e-06	0.000105	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.79e-06	0.000105	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.64e-06	0.000101	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	3.52e-06	9.77e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.46e-06	9.59e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.4e-06	9.44e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.35e-06	9.31e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.31e-06	9.18e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	3.3e-06	9.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.29e-06	9.12e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.22e-06	8.95e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	3.16e-06	8.77e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.12e-06	8.66e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.08e-06	8.56e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.08e-06	8.55e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.06e-06	8.49e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.04e-06	8.43e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3.01e-06	8.36e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.95e-06	8.19e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.92e-06	8.11e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.91e-06	8.06e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.88e-06	7.99e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.71e-06	7.52e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.66e-06	7.37e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.57e-06	7.14e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.57e-06	7.13e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.46e-06	6.83e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.35e-06	6.53e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.23e-06	6.19e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.04e-06	5.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.99e-06	5.51e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.9e-06	5.27e-05	CbGpPWpGaD
